#WODC USA Session preview - Overcoming challenges in Rare Disease Health Research and Orphan Drug Program commercialization

#WODC USA Session preview – Overcoming challenges in Rare Disease Health Research and Orphan Drug Program commercialization

In Orphan Drug Congress, Orphan Drugs Live by Freya SmaleLeave a Comment

#WODC USA Session preview – Overcoming challenges in Rare Disease Health Research and Orphan Drug Program commercialization

What are the benefits of attending your workshop?

Mapi and industry experts will share their knowledge and experience on creating rare disease and orphan drug programs, from understanding disease indications and involvement with payers to real world data and regulatory issues.

What are the topics you’re going to cover?

  • “The Process of Understanding the Person with the Indication” – Kelly Franchetti
  • “Market Access Challenges for Rare Diseases – Recent Developments in HTA & Reimbursement Decision-Making” – Charles Makin
  • “Orphan Drug and Rare Diseases – Requirements for Real World Data: Generating Data to Gain and Keep Market Access Considerations for Orphan Drugs in Europe”- Will Maier
  • “Regulatory Hurdles Orphan Drug – Are They Increasing?” – Patricia Anderson

Speakers

  • Kelly Franchetti, RN, CCRN, CEN, Executive Director, Global Patients Insights and Engagement
  • Charles Makin, BSPharm, MS, MBA, MM, Vice President, Real World Strategy & Analytics
  • Will Maier, MD, MPH, Chief Scientific Officer
  • Patricia Anderson, Vice President, Regulatory Services

Agenda Overview

1:00

Opening Introductions:

Will Maier, PhD, MPH, Chief Scientific Officer

 1:10–2:20

The Process of Understanding the Person with the Indication

Kelly Franchetti, RN, CCRN, CEN, Executive Director, Global Patients Insights and Engagement

2:20–3:00

Market Access Challenges for Rare Diseases – Recent Developments in HTA and Reimbursement Decision-Making Considerations for Orphan Drugs in Europe

Charles Makin, BSPharm, MS, MBA, MM, Vice President, Mapi Real World Strategy & Analytics

 3:20–4:00

Orphan Drug and Rare Diseases – Requirements for Real World Data: Generating Data to Gain and Keep Market Access

Will Maier, PhD, MPH, Chief Scientific Officer

 4:00–4:30

Regulatory Hurdles Orphan Drug – Are They Increasing?

Patricia Anderson, Vice President, Regulatory Services

Sponsored by MAPI

Register your ticket now for you chance to get involved in this workshop!

World Orphan Drug Congress USA 2016

Leave a Comment